BLOG SOBRE TEMAS DE BIOTECNOLOGÍA

Concluído el proyecto "MULTIFLOW"

16/05/2018

Esta semana, el 16 de Mayo de 2018, ha concluído el proyecto "MULTIFLOW" subvencionado por el Centro para el Desarrollo Tecnológico Industrial con cargo al programa FEDER INNTERCONECTA y realizado por las empresas Vitro, Master Diagnóstica, Destina Genómica y Rekom Biotech. La clausura del proyecto se llevó a cabo en Sevilla, en las instalaciones de la empresa Vitro. El equipo multidisciplinar formado por el consorcio "MULTIFLOW" ha concluido con éxito todos los objetivos técnicos planteados en el proyecto. Desde Rekom Biotech agradecemos a nuestros colaboradores del consorcio el estupendo ambiente de trabajo y colaboración que ha caracterizado al proyecto desde sus inicios.

Diseño al servicio de la ciencia

Human cytomegalovirus (HCMV) is endemic to populations throughout the world, and 50-80% of the adults in developed nations are sero-positive for this virus. Commercial ELISAs for detecting IgG are very sensitive and specific. Nevertheless, there are several problems regarding IgM detection. One of the difficulties that the diagnostic laboratory has faced over the past 10 years is the lack of agreement between commercial tests for the detection of CMV-specific IgM. This lack of agreement has its roots in the different viral preparations used to detect IgM antibodies to CMV. Rekom Biotech has performed the design of a new CMV recombinant polyepitope chimeric antigen (RAG0109), composed by different sensitive and specific antigenic determinants from some CMV proteins. This recombinant polyepitope chimeric antigen was tested in parallel with other CMV bio-markers such as the Rekom Biotech CMV recombinant proteins pp150 (RAG0091), pp52 (RAG0090) and pp65 (RAG0016). The in house indirect IgM ELISA assay was carried out by using a battery of pre-validated sera with the commercial ELISA capture IgM test from Vidas:

Figure 1: Indirect IgM ELISA assay. Proteins were coating the plates at a final concentration of 1 µg/ml. All these experiments used anti-IgG as sorbent and anti-IgM-HRP. Sera were used in a 1:100 dilution. P means pre-validated sera by the Vidas test as positive; N means pre-validated sera by the Vidas test as negative.

These preliminary experiments suggest that the recombinant polyepitope chimeric antigen designed and produced by Rekom Biotech, RAG0109, recovers some pre-validated IgM positive sera which are not initially detected by two of the best antigens described in bibliography for CMV diagnosis: pp52 and pp150, showing the presence in merely one antigen of some important epitopes for this specific diagnostic.

To find more interesting information on regards recombinant antigen RAG0109, please click here.

Written by Ana Camacho.

REKOM BIOTECH implementa la nueva norma ISO 9001:2015

12/04/2018

Nuestro compromiso de garantizar el más alto nivel de calidad en el diseño y producción de antígenos recombinantes continúa después de implementar la nueva norma ISO:9001-2015.

REKOM BIOTECH en MEDLAB ASIA PACIFIC 2018

06/04/2018

Rekom Biotech asiste a MEDLAB ASIA PACIFIC, del 2 al 4 de abril de 2018, con el objetivo de consolidar su presencia en el mercado asiático. Durante la feria, nuestros compañeros, la Dra. Ana Camacho (CEO & CSO) y Rafael Texeira (Export Manager), aprovecharon para reunirse con potenciales clientes interesados tanto en nuestra gama de antígenos recombinantes como en nuestros servicios de diseño de antígenos. Además, se presentó la nueva línea de alérgenos y se visitó a los actuales clientes que Rekom Biotech tiene en países de la zona como China, India, Japón o Corea.